Efficacy News and Research

RSS

Endo Pharmaceuticals supports efforts to bring first ever treatment guidelines for Peyronie's Disease

Endo Pharmaceuticals Inc., a subsidiary of Endo International plc, supports efforts to bring the medical community the first ever treatment guidelines for Peyronie's Disease (PD), a condition in which collagen plaque, or scar tissue, develops on the shaft of the penis, and may harden and reduce flexibility.

19 May 2015

Study quantifies different mutational profiles of tumour cell clusters in patients with bowel cancer

Bowel cancer is often driven by mutations in one of several different genes, and a patient can have a cancer with a different genetic make-up to another patient's cancer. Identifying the molecular alterations involved in each patient's cancer enables doctors to choose drugs that best target specific alterations.

19 May 2015

Monash University-led researchers call for HCV patients to gain improved access to effective drugs

In a letter to the Medical Journal of Australia published today, a Monash University-led team is asking for hepatitis C virus patients to gain improved access to drugs to prevent liver related deaths.

19 May 2015

Immune Pharmaceuticals announces Q1 2015 financial results; files Quarterly Report on Form 10-Q

Immune Pharmaceuticals Inc. announced financial results for the first quarter ended March 31, 2015. Immune filed its Quarterly Report on Form 10-Q for the first quarter of 2015 on Friday, May 15, 2015.

18 May 2015

New findings could help better understand neurodegenerative diseases

Researchers at the Luxembourg Centre for Systems Biomedicine (LCSB), of the University of Luxembourg, have, under Dr. Manuel Buttini, successfully measured metabolic profiles, or the metabolomes, of different brain regions, and their findings could help better understand neurodegenerative diseases.

18 May 2015

Endo Announces Updated XIAFLEX® Label in Patients with Dupuytren’s Contracture

DC is a chronic condition affecting the hand in which abnormal buildup of collagen can cause the fingers to bend and be drawn in toward the palm...

18 May 2015

New research confirms the efficacy of Hilterapia laser technique for treating tendinitis

A recent study conducted by the researchers Gabrhel J., Popracová Z., Tauchmannová H. and M. Nemšák on the application of Hilterapia®, produced by ASAlaser - a company for over 30 years at the forefront of the study and development of therapeutic laser solutions - in Achilles tendinopathy and in serious tendons and ligaments disorders has confirmed its full effect.

18 May 2015

No data exists to support long-term efficacy, safety of e-cigarettes as smoking cessation tool

There is little reliable evidence that electronic cigarettes are effective for long-term smoking cessation, according to a new analysis of the currently available research which was presented at the 2015 American Thoracic Society International Conference.

18 May 2015

Botulinum toxin A effective for treating bladder disorders

While Botulinum toxin A (BTX-A), known to the public as Botox, is commonly associated with smoothing wrinkles for a more youthful appearance, three studies presented at the 110th Annual Scientific Meeting of the American Urological Association are proving BTX-A to be more than just a cosmetic solution.

17 May 2015

Meta-analysis supports ambrisentan efficacy

A meta-analysis supports the efficacy of ambrisentan in patients with pulmonary arterial hypertension.

15 May 2015

Study finds botulinum toxin injections in epicardial fat pads reduce AF risk immediately following surgery and after one year of follow-up

AF is the most common arrhythmia complicating cardiac surgery and occurs in approximately 30-40 percent of patients undergoing CABG surgery...

15 May 2015

Mifepristone-eribulin combination clinically active in triple-negative breast cancer patients

Corcept Therapeutics Incorporated, a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced results of a multi-center Phase 1/2 dose-escalation study of mifepristone and chemotherapy drug eribulin (Halaven) that show it is well tolerated and clinically active in patients with triple-negative breast cancer.

15 May 2015

Chemical drug safely controls side effects associated with haploidentical stem cell transplantation

Researchers in the Center for Cell and Gene Therapy at Baylor College of Medicine, Houston Methodist and Texas Children's Hospital have found that a single dose of an otherwise harmless drug can safely control the severe and often lethal side effects associated with haploidentical stem cell transplantation.

15 May 2015

Study finds similarity in clinical progression between human patients and Huntington's disease monkeys

Transgenic Huntington's disease monkeys show similarity to humans with Huntington's in their progressive neurodegeneration and decline of motor control, scientists from Yerkes National Primate Research Center, Emory University, report.

14 May 2015

TB Alliance announces start of clinical trial to treat XDR-TB

TB Alliance and its partners announced the start of a clinical trial of a new regimen to treat extensively drug-resistant tuberculosis (XDR-TB). It is the first study to test an all-oral drug regimen, comprised of drugs with minimal pre-existing resistance, that has the potential to shorten, simplify, and improve treatment for XDR-TB.

14 May 2015

New approach to vaccine development is 97 per cent efficacious and could eliminate shingles

A new vaccine has proven almost completely effective in preventing shingles (disease medical name: herpes zoster), an extremely painful nerve infection which affects a third of Australians; most over the age of 50...

13 May 2015

Invectys begins INVAC-1 phase I clinical trial in cancer patients

Invectys announces today that it has initiated a phase I clinical trial of its immunotherapeutic drug candidate INVAC-1.

13 May 2015

Study evaluates VolitionRx's proprietary Nucleosomics platform in most prevalent cancers

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that it has accelerated its large independent prospective study evaluating its proprietary Nucleosomics platform at University Hospital Bonn in Germany.

13 May 2015

European Investment Bank supports Bavarian Nordic’s development of Ebola and cancer vaccines

The European Investment Bank (EIB), the world’s largest multilateral bank, today reaffirmed its firm commitment to respond to the Ebola pandemic. The Bank has provided a EUR 50 million loan to Bavarian Nordic, an international biopharmaceutical company, for accelerated development of an Ebola vaccine with long-term efficacy. The financing is also backing research into vaccines for treating other infectious diseases and multiple cancer indications.

12 May 2015

Merck KGaA, Darmstadt, Germany granted FDA Fast Track designation for development of evofosfamide

Merck KGaA, Darmstadt, Germany, a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials today announced that the U.S. Food and Drug Administration has granted Fast Track designation for the development of evofosfamide (previously known as TH-302), administered in combination with gemcitabine, for the treatment of previously untreated patients with metastatic or locally advanced unresectable pancreatic cancer.

12 May 2015

Efficacy News and Research

Endo Pharmaceuticals supports efforts to bring first ever treatment guidelines for Peyronie's Disease

Study quantifies different mutational profiles of tumour cell clusters in patients with bowel cancer

Monash University-led researchers call for HCV patients to gain improved access to effective drugs

Immune Pharmaceuticals announces Q1 2015 financial results; files Quarterly Report on Form 10-Q

New findings could help better understand neurodegenerative diseases

Endo Announces Updated XIAFLEX® Label in Patients with Dupuytren’s Contracture

New research confirms the efficacy of Hilterapia laser technique for treating tendinitis

No data exists to support long-term efficacy, safety of e-cigarettes as smoking cessation tool

Botulinum toxin A effective for treating bladder disorders

Meta-analysis supports ambrisentan efficacy

Study finds botulinum toxin injections in epicardial fat pads reduce AF risk immediately following surgery and after one year of follow-up

Mifepristone-eribulin combination clinically active in triple-negative breast cancer patients

Chemical drug safely controls side effects associated with haploidentical stem cell transplantation

Study finds similarity in clinical progression between human patients and Huntington's disease monkeys

TB Alliance announces start of clinical trial to treat XDR-TB

New approach to vaccine development is 97 per cent efficacious and could eliminate shingles

Invectys begins INVAC-1 phase I clinical trial in cancer patients

Study evaluates VolitionRx's proprietary Nucleosomics platform in most prevalent cancers

European Investment Bank supports Bavarian Nordic’s development of Ebola and cancer vaccines

Merck KGaA, Darmstadt, Germany granted FDA Fast Track designation for development of evofosfamide

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News